ロード中...
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab
The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement‐mediated attack, primarily through the over‐expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Trastuzumab, an anti‐ HER2 monoclonal antibody, approved for th...
保存先:
| 出版年: | Mol Oncol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528480/ https://ncbi.nlm.nih.gov/pubmed/23474221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.02.011 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|